Search

Displaying results 761 - 770 of 7639 in total
  1. Drug

    Pregabalin

    go.drugbank.com/drugs/DB00230
    ApprovedInvestigational

    [L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161] … [A187190] Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent

    Products: Nb-pregabalin
  2. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.

    Categories: Non Potassium Sparing Diuretics
  3. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]

  4. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … [L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors.

  5. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.

  6. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.

  7. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract … infections, including pyelonephritis caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens.

  8. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    Its pharmacokinetic properties are not reported to be affected by factor Xa inhibitors [A35518]. … Andexanet alfa retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation

  9. Indication

    Letterer-Siwe disease

    go.drugbank.com/conditions/DBCOND0021755
    Drugs: Vinblastine
    Synonyms: Langerhans cell histiocytosis, no ICD-O subtype, Langerhans cell histiocytosis, no International Classification of Diseases for Oncology subtype
  10. Drug

    Aspartic acid

    go.drugbank.com/drugs/DB00128
    ApprovedInvestigationalNutraceutical

    One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

    Mixtures: Vamin N, OLIMEL N9-840 İNFÜZYONLUK AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML